These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 11956088)

  • 21. Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy.
    Ino Y; Saeki Y; Fukuhara H; Todo T
    Clin Cancer Res; 2006 Jan; 12(2):643-52. PubMed ID: 16428511
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potent antitumor activity after systemic delivery of a doubly fusogenic oncolytic herpes simplex virus against metastatic prostate cancer.
    Nakamori M; Fu X; Pettaway CA; Zhang X
    Prostate; 2004 Jun; 60(1):53-60. PubMed ID: 15129429
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhancement of antitumor activity of herpes simplex virus gamma(1)34.5-deficient mutant for oral squamous cell carcinoma cells by hexamethylene bisacetamide.
    Naito S; Obayashi S; Sumi T; Iwai S; Nakazawa M; Ikuta K; Yura Y
    Cancer Gene Ther; 2006 Aug; 13(8):780-91. PubMed ID: 16645620
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Coadministration of a herpes simplex virus-2 based oncolytic virus and cyclophosphamide produces a synergistic antitumor effect and enhances tumor-specific immune responses.
    Li H; Zeng Z; Fu X; Zhang X
    Cancer Res; 2007 Aug; 67(16):7850-5. PubMed ID: 17699791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potent oncolytic activity of multimutated herpes simplex virus G207 in combination with vincristine against human rhabdomyosarcoma.
    Cinatl J; Cinatl J; Michaelis M; Kabickova H; Kotchetkov R; Vogel JU; Doerr HW; Klingebiel T; Driever PH
    Cancer Res; 2003 Apr; 63(7):1508-14. PubMed ID: 12670897
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of solid sarcomas in immunocompetent mice with novel, oncolytic herpes simplex viruses.
    Sugiura S; Goshima F; Takakuwa H; Sata T; Nakashima T; Nishiyama Y
    Otolaryngol Head Neck Surg; 2004 Apr; 130(4):470-8. PubMed ID: 15100647
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oncolysis by viral replication and inhibition of angiogenesis by a replication-conditional herpes simplex virus that expresses mouse endostatin.
    Mullen JT; Donahue JM; Chandrasekhar S; Yoon SS; Liu W; Ellis LM; Nakamura H; Kasuya H; Pawlik TM; Tanabe KK
    Cancer; 2004 Aug; 101(4):869-77. PubMed ID: 15305421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
    Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
    J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models.
    Terada K; Wakimoto H; Tyminski E; Chiocca EA; Saeki Y
    Gene Ther; 2006 Apr; 13(8):705-14. PubMed ID: 16421599
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An HSV-1 amplicon system for prostate-specific expression of ICP4 to complement oncolytic viral replication for in vitro and in vivo treatment of prostate cancer cells.
    Lee CY; Bu LX; Rennie PS; Jia WW
    Cancer Gene Ther; 2007 Jul; 14(7):652-60. PubMed ID: 17479106
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system.
    Fukuhara H; Ino Y; Kuroda T; Martuza RL; Todo T
    Cancer Res; 2005 Dec; 65(23):10663-8. PubMed ID: 16322208
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Virotherapy with a type 2 herpes simplex virus-derived oncolytic virus induces potent antitumor immunity against neuroblastoma.
    Li H; Dutuor A; Tao L; Fu X; Zhang X
    Clin Cancer Res; 2007 Jan; 13(1):316-22. PubMed ID: 17200370
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The construction of recombinant type I herpes simplex virus carrying GALV.fus gene and its antitumor effect in nude mice].
    Zhu M; Yang JR; Jiang YQ; Chen SF; Fu XP; Tian ZD
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2011 Mar; 42(2):152-6. PubMed ID: 21500543
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene.
    Pawlik TM; Nakamura H; Mullen JT; Kasuya H; Yoon SS; Chandrasekhar S; Chiocca EA; Tanabe KK
    Cancer; 2002 Sep; 95(5):1171-81. PubMed ID: 12209705
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity.
    Irving J; Wang Z; Powell S; O'Sullivan C; Mok M; Murphy B; Cardoza L; Lebkowski JS; Majumdar AS
    Cancer Gene Ther; 2004 Mar; 11(3):174-85. PubMed ID: 14726958
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Herpes simplex virus delivery to orthotopic rectal carcinoma results in an efficient and selective antitumor effect.
    Kolodkin-Gal D; Edden Y; Hartshtark Z; Ilan L; Khalaileh A; Pikarsky AJ; Pikarsky E; Rabkin SD; Panet A; Zamir G
    Gene Ther; 2009 Jul; 16(7):905-15. PubMed ID: 19440231
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus.
    Anderson BD; Nakamura T; Russell SJ; Peng KW
    Cancer Res; 2004 Jul; 64(14):4919-26. PubMed ID: 15256464
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer.
    Coukos G; Makrigiannakis A; Kang EH; Caparelli D; Benjamin I; Kaiser LR; Rubin SC; Albelda SM; Molnar-Kimber KL
    Clin Cancer Res; 1999 Jun; 5(6):1523-37. PubMed ID: 10389942
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers.
    Varghese S; Rabkin SD; Liu R; Nielsen PG; Ipe T; Martuza RL
    Cancer Gene Ther; 2006 Mar; 13(3):253-65. PubMed ID: 16179929
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dual promoter-controlled oncolytic adenovirus CG5757 has strong tumor selectivity and significant antitumor efficacy in preclinical models.
    Li Y; Idamakanti N; Arroyo T; Thorne S; Reid T; Nichols S; VanRoey M; Colbern G; Nguyen N; Tam O; Working P; Yu DC
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8845-55. PubMed ID: 16361574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.